Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Cellares inks long‑term lease in Leiden to expand automated cell‑therapy manufacturing network

January 17, 2026

Cellares signed a long‑term lease for a Smart Factory facility at Leiden Bio Science Park to establish a European hub for automated cell‑therapy development and manufacturing. The...

Agenus seals $141M collaboration with Zydus to accelerate BOT+BAL immunotherapy and US manufacturing

January 17, 2026

Agenus closed a previously announced $141 million strategic collaboration with Zydus Lifesciences to advance the botensilimab plus balstilimab (BOT+BAL) immunotherapy program. The deal secures...

ImmunityBio CAR‑NK posts durable complete responses

January 17, 2026

ImmunityBio reported early clinical activity from its off‑the‑shelf CD19 CAR‑NK program in Waldenström’s macroglobulinemia, with patients achieving durable complete responses without...

ARPA‑H backs 3D‑printed livers: UC San Diego lands major grant

January 17, 2026

UC San Diego secured an ARPA‑H Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) award to develop patient‑specific, 3D‑bioprinted human livers, receiving up to $25.77 million...

Boston Scientific goes all‑in: $14.5B bid for Penumbra

January 17, 2026

Boston Scientific announced a cash‑and‑stock agreement to acquire Penumbra for about $14.5 billion, moving to expand its footprint in thrombectomy, embolization and other interventional vascular...

Tecvayli shows survival gains in earlier multiple myeloma – J&J

January 17, 2026

Johnson & Johnson reported positive Phase 3 trial results showing Tecvayli reduced the risk of progression or death by 71% in patients with relapsed multiple myeloma compared with standard...

MRD testing: BloodPAC issues standards as labs roll out assays

January 17, 2026

BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) MRD assays to harmonize limit‑of‑detection, accuracy, precision and robustness testing...

Novo Nordisk Foundation commits big to scale Danish biotech innovation

January 17, 2026

The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million) to expand the BioInnovation Institute (BII), scaling its support from Danish startups to a Europe‑wide innovation...

Big tech and lab automation collide: NVIDIA deals with Thermo Fisher and Lilly

January 17, 2026

Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to embed the company’s AI platform into scientific instruments and lab workflows, aiming to accelerate automation,...

Cellares expands IDMO footprint with Leiden Smart Factory lease

January 17, 2026

Cellares signed a long‑term lease for a new integrated development and manufacturing organization (IDMO) Smart Factory in Leiden Bio Science Park to serve as the company’s European headquarters....

Gene‑drive mosquitoes validated against diverse malaria strains in Tanzania

January 17, 2026

Researchers adapted a previously developed gene‑drive strategy and tested it in secure facilities in Tanzania, engineering Anopheles mosquitoes to express antiparasitic effectors (MM‑CP) and...

FDA grants RMAT to iRegene’s iPSC‑derived Parkinson’s therapy

January 17, 2026

The U.S. FDA awarded Regenerative Medicine Advanced Therapy (RMAT) designation to iRegene’s NouvNeu001, making it the first allogeneic iPSC‑derived cell therapy to hold both FDA Fast Track and...

Off‑the‑shelf CAR‑NK: Durable complete responses in Waldenström

January 17, 2026

Early clinical data show an allogeneic CAR‑NK therapy produced durable complete responses in patients with Waldenström’s macroglobulinemia when combined with anti‑CD20 therapy. ImmunityBio...

ARPA‑H backs UCSD: $25.8M push to 3D‑print patient‑specific livers

January 17, 2026

UC San Diego won a long‑term ARPA‑H award to develop patient‑specific, 3D‑bioprinted human livers with the goal of creating transplant‑ready organs from a patient’s own cells. The five‑year,...

Novo Nordisk Foundation Pours DKK5.5B ($850M) into BioInnovation Institute

January 17, 2026

The Novo Nordisk Foundation committed up to DKK 5.5 billion (about $850–$857 million) to Denmark’s BioInnovation Institute to scale early‑stage life‑science commercialization across Europe. The...

Tecvayli survival win: J&J reports major Phase 3 benefit in multiple myeloma

January 17, 2026

Johnson & Johnson announced Phase 3 results showing Tecvayli improved survival and progression‑free outcomes in patients with relapsed multiple myeloma compared with standard regimens, per company...

Boston Scientific to buy Penumbra for $14.5B – Big play in thrombectomy

January 17, 2026

Boston Scientific agreed to acquire Penumbra for $14.5 billion in cash and stock to expand into thrombectomy and embolization devices, the companies announced. The deal adds Penumbra’s...

FDA grants RMAT to iRegene’s iPSC therapy – Regulatory double‑play for Parkinson’s

January 17, 2026

The FDA awarded Regenerative Medicine Advanced Therapy (RMAT) designation to iRegene Therapeutics’ lead off‑the‑shelf, chemically induced iPSC product NouvNeu001 for Parkinson’s disease, adding to...

BloodPAC issues MRD validation protocols – Toward analytic standards for ctDNA

January 17, 2026

The BloodPAC consortium published generic analytic validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays aimed at minimal residual disease (MRD) monitoring. The protocols,...

Myriad maps MRD rollout: Sequenced launches and reimbursement playbook

January 17, 2026

Myriad Genetics outlined a staged commercial plan for tissue‑informed MRD assays, beginning with a breast cancer MRD test in early 2026 and follow‑on launches for renal, colorectal, endometrial,...